Fortune Business Insights predicts the Global Intravenous Immunoglobulin Market to reach a value of US$ 15,789.1 Mn from US$ 9,787.6 Mn. The forecast period is set from 2018 and the market is expected to grow at a CAGR of 6.2%. All information related to the market is provided in the report, titled, “Intravenous Immunoglobulin Market Size, Share and Global Trend by Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), Form (Liquid, Lyophilized), End User (Hospitals, Clinics, Homecare) & Geography Forecast till 2025”. The rising incidence of immunodeficiency diseases in both emerging and developed nations is propelling growth of the Intravenous Immunoglobulin market.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/intravenous-immunoglobulins-market-100593

Some of the leading companies that are operating in the market are:

Shire (Takeda Pharmaceutical Company Limited)
CSL Behring
Grifols, S.A.
Kedrion S.p.A
Octapharma
Bio Products Laboratory Ltd.
Biotest AG
China Biologic Products Holdings, Inc.
LFB SA
Shanghai RAAS Blood Products Co., Ltd.
As per the report, the Global Intravenous Immunoglobulin Market is expected to be dominated by the primary immunodeficiency segment with respect to segmentation by indication. In 2017, the primary immunodeficiency segment held 28.6% of the overall intravenous immunohlobulins market share. This is owing to the increasing prevalence of primary immunodeficiency that there is rise in demand for immunoglobulins. Beside this, the assending focus on treating primary immunodeficiency is further expected to boost the market. Owing to the factors mentioned above, this segment is anticipated to continue dominating the market in the forecast duration as well.

Increasing Adoption of Immunoglobulins to Help Asia Pacific Register Fastest Growth

According to the report, The Global Intravenous Immunoglobulin Market was dominated by North America with a market value of US$ 5,587.4 Mn in 2017. The region is likley to remain dominant through the forecast period as well due to the presence of first line treatment for critical immune disorders. Other factors boosting the market in the region are rising number of patients and efficient results of the intravenous immunoglobulin treatment.

On the other side, the market in Asia Pacific is anticipated to grpow at faster rate in the coming years on account of the rise in awareness about the treatment option avaiulable for immunologic deficiencies. In addition to this, the rise in adoption and expenditure of immunoglobulins in economies such as Japan, China,and Indiais anticipated to boost the market in the region.